Drug CategoryDrugIHD Dosing

Administration Timing Around HD Session

AntibioticsGentamicinLD 2mg/kg IV, then 1-1.5mg/kg IV QHDAdminister Post-HD

Molecular Weight    (Da)

Excreted Unchanged (%)Normal Half-Life (Hours)ESRD Half-Life (Hours)Plasma Protein Binding (%)Volume of Distribution (L/kg)Dialytic Plasma Clearance (ml/min)% Dialyzed
478951.820-600-300.23-0.2624-11638-60 (high flux)


  • Al-Homrany M, Irshaid Y, El Sherif A, Omar H. Pharmacokinetics of gentamicin in hemodialysis patients: a comparative study between diabetic and non-diabetic patients. International urology and nephrology 2009; 41(3), 663-9.
  • Amin N, Padhi I, Touchette M, Patel R, Dunfee T, Anandan J. Characterization of gentamicin pharmacokinetics in patients hemodialyzed with high-flux polysulfone membranes. American journal of kidney diseases (the official journal of the National Kidney Foundation) 1999; 34(2), 222-7.
  • Aronoff GR, Bennett WM, Berns JS, Brier ME, Kasbekar N, Mueller BA, et al. Drug Prescribing in Renal Failure. Philadelphia: American College of Physicians;2007.
  • Bauer L. Rebound Gentamicin Levels after Hemodialysis. Therapeutic Drug Monitoring 1982; 4, 99-101.
  • Chan R, Benner E, Hoeprich P. Gentamicin therapy in renal failure: a nomogram for dosage. Annals of internal medicine 1972, 76(5), 773-8.
  • Christopher T, Korn D, Blair A, Forrey A, O’Neill M, Cutler R. Gentamicin pharmacokinetics during hemodialysis. Kidney international 1974; 6(1), 38-44.
  • Christopher T, Graham, Blair A, Forrey A, Cutler R. Hemodialyzer Clearances of Gentamicin , Kanamycin , and Flucytosine , with a Technique for Planning Therapy. Journal of Pharmacokinetics and Biopharmaceutics 1976; 4(5), 427-41.
  • Curtis J, McDonald S, Weston J. Parenteral administration of gentamicin in renal failure: patients undergoing intermittent haemodialysis. British medical journal 1967; 2(5551), 537-9.
  • Danish M, Schultz R, Jusko J, Jusko W. Pharmacokinetics of Gentamicin and Kanamycin During Hemodialysis. Antimicrobial agents and chemotherapy 1974; 6(6), 841-9.
  • Dijkmans B, Mattie H. Predictability of serum concentrations of aminoglycosides after haemodialysis. European journal of clinical pharmacology 1987; 33(2), 179-83.
  • DrugBank [Online]. 2012 Apr 12 [cited 2012 May 6]; Available from: URL:
  • Heintz B, Matzke G, Dager W. Antimicrobial dosing concepts and recommendations for critically ill adult patients receiving continuous renal replacement therapy or intermittent hemodialysis. Pharmacotherapy 2009; 29(5), 562-77.
  • Kirkpatrick C, Duffull S, Begg E. Pharmacokinetics of gentamicin in 957 patients with varying renal function dosed once daily. British journal of clinical pharmacology 1999; 47(6), 637-43.
  • Matzke G. Status of Hemodialysis of Drugs in 2002. Journal of Pharmacy Practice 2002; 15(5), 405-418.
  • Matzke G, Halstenson C, Keane W. Hemodialysis Elimination Rates and Clearance of Gentamicin and Tobramycin. Antimicrobial agents and chemotherapy 1984; 25(1), 128-32.
  • Sowinski K, Magner S, Lucksiri A, Scott M, Hamburger R, Mueller B. Influence of hemodialysis on gentamicin pharmacokinetics, removal during hemodialysis, and recommended dosing. Clinical journal of the American Society of Nephrology (CJASN) 2008; 3(2), 355-61.
  • Teigen M, Duffull S, Dang L, Johnson D. Dosing of gentamicin in patients with end-stage renal disease receiving hemodialysis. Journal of clinical pharmacology 2006; 46(11), 1259-67.
  • Vercaigne L, Ariano R, Zacharias J. Bayesian pharmacokinetics of gentamicin in a haemodialysis population. Clinical pharmacokinetics 2004; 43(3), 205-10.
  • Wright N, Bhamjee A. Gentamicin extraction from an anuric patient by combined haemodialysis and charcoal haemoperfusion. Postgraduate medical journal 1980; 56(652), 140-1.